| REVIEW ARTICLE |
|
| Year : 2022 | Volume
: 1
| Issue : 4 | Page : 196-202 |
|
|
Clinical pharmacology of cefazolin
Gian Maria Pacifici
via Sant’Andrea 32, Pisa, Italy
Correspondence Address:
Prof. Gian Maria Pacifici
via Sant’Andrea 32, 56127 Pisa
Italy
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/abhs.abhs_31_22
|
|
|
Cefazolin is a first-generation cephalosporin that is active against gram-positive bacteria and has modest activity against gram-negative organisms, and cefazolin is excreted by glomerular filtration. The efficacy and safety of cefazolin and cefazolin concentration in body tissues have been described. Cefazolin pharmacokinetics have been studied; six patients received cefazolin at a dose of 1 g thrice daily and one patient received cefazolin at a dose of 2 g once daily and this patient had acute kidney injury. The pharmacokinetics of cefazolin have been studied. The prophylaxis, treatment, and trials with cefazolin have been reported. The penetration of cefazolin into the cerebrospinal fluid has been studied. Cefazolin treats the meningitis caused by Staphylococcus meningitis or by methicillin-susceptible S. aureus and cefazolin may become resistant to bacteria. Cefazolin freely crosses the human placenta and poorly migrates into the breast milk. The aim of this review was to describe cefazolin efficacy and safety, tissue concentration, pharmacokinetics, prophylaxis, treatment, trials, penetration into the cerebrospinal fluid, treatment of bacterial meningitis, resistance, transfer across the human placenta, and migration into the breast milk. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
